Clinical evaluation of siddha medicine Pavala silasathu parpam for Type II Diabetes mellitus

Single centric Non randomized open clinical trial Phase II in Madhumegam (Type II Diabetes mellitus) with Siddha Medicine Pavala silasathu parpam - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067508

Enrollment

Registered

2024-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Pavala silasathu parpam: This Siddha drug will be given as 130mg,BD dose with Ghee,for 90 days for the management of Type II Diabetes mellitus. Control Intervention1: Not Applicable: No

Eligibility

Inclusion criteria

Inclusion criteria: 1.sex:all genders 2.Polyuria 3.Polydipsia 4.Polyphagia 5.HbA1C-6.5%-8%

Exclusion criteria

Exclusion criteria: 1 Pregnant women 2 Lactating mothers 3 Insulin dependent Diabetes mellitus 4 Patient having severe comorbidity like Cardiovascular disease 5 Diabetic nephropathy 6 Diabetic retinopathy 7 Benign Prostatic hyperplasia 8 Diabetes insipidus The above criteria will be excluded clinically or based on the available medical reports.

Design outcomes

Primary

Measure	Time frame
Reduction in HbA1C level (atleast 20%)Timepoint: 90 days	—

Secondary

Measure	Time frame
Reduction in clinical symptoms Polyuria,Polydipsia,Polyphagia &FatigueTimepoint: 90 days	—

Countries

India

Contacts

Public ContactTheenathayalan S

Government Siddha Medical College Chennai.

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026